O1–06–07: Immunotherapy with antibodies to N–terminal amyloid–β peptides reduces cerebral amyloid angiopathy in PDAPP mice
| Autor: | Peter Seubert, Guriq Basi, Tam Doan, Robin Barbour, Terry Guido, Dora Games, Sally Schroeter, Ming Chen, Karen Khan |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Pathology
medicine.medical_specialty Amyloid biology Epidemiology business.industry Health Policy medicine.medical_treatment Immunotherapy medicine.disease Epitope Psychiatry and Mental health Cellular and Molecular Neuroscience Cerebral circulation Developmental Neuroscience Hemosiderin mental disorders biology.protein Medicine Immunohistochemistry Neurology (clinical) Cerebral amyloid angiopathy Geriatrics and Gerontology Antibody business |
| Zdroj: | Alzheimer's & Dementia. 2 |
| ISSN: | 1552-5279 1552-5260 |
| DOI: | 10.1016/j.jalz.2006.05.067 |
| Popis: | Passive immunotherapy with amyloid(A ) antibodies reduces a number of AD pathologies including parenchymal A plaques, neuritic dystrophy, synaptic loss, and memory function in mouse models, and many of these effects are beginning to be seen in AD patients. In addition to parenchymal deposition of amyloid, AD is also characterized by amyloid fibrils in the cerebral vasculature in the majority of patients, a condition called cerebral amyloid angiopathy (CAA). Previous studies have suggested that immunotherapy does not clear and may increase CAA and the incidence of microhemorrhage. In the present study we demonstrate that certain immunotherapies are surprisingly highly efficacious in removing CAA and that the incidence of microhemorrhage can be modulated by dosage. We examined the effects of passive immunization on CAA in 2 PDAPP mouse studies: one a comparison of antibodies to different A epitopes (3D6, A 1-5; 12A11 and 10D5, A 3-7; 266 A 16-23) at one dose, and a 3D6 dose-response study at 3 doses. CAA clearance and microhemorrhage incidence were assessed after 6 months using A IHC and hemosiderin detection. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|